Skip to main content

Table 2 Analysis of the effects of phenotypes on TTF and OS.

From: No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

Genotype

N

%

Median TTF

(months)

p value

Median OS

(months)

p value

CYP2C19

      

EM

266

78

28.7

0.4

(0.4)

73.9

0.4

(0.5)

IM + PM

73

22

25.1

 

65.6

 

CYP2D6

      

UM + EM

127

56

30.7

0.9

(0.8)

65.9

0.2

(0.4)

IM + PM

101

44

25.4

 

80.7

 
  1. Values in italics are adjusted for prognostic-related factors (TTF: β2-microglobulin.
  2. OS: β2-microglobulin, creatinine and Durie-Salmon stage) and are shown in parentheses.